Mouse data presented at ASM Microbe 2026 point to microbially modified bile acids and a host liver receptor as a candidate link between intermittent hypoxia and arterial plaque.
When oxygen levels plunge during a sleep apnea episode, the damage to the cardiovascular system may not begin in the airway or the heart at all. It may begin in the gut, where microbes reshape bile acids into chemical messengers that travel to artery walls and accelerate the buildup of plaque.
That is the case Celeste Allaband, DVM, Ph.D., of the University of California, San Diego, made this week at ASM Microbe 2026 in Washington, D.C., describing a mouse experiment in which removing a single liver receptor appeared to blunt much of the arterial damage caused by sleep apnea-like oxygen swings.
The work, reported by SciTechDaily from the conference press release, centers on a familiar atherosclerosis model: ApoE knockout mice, which develop arterial plaque on a normal diet. Allaband's team compared those animals to a double-knockout strain that also lacks the farnesoid X receptor, or FXR, a nuclear receptor in the liver and intestine that responds to bile acids. Both groups were exposed to intermittent hypoxia, the drop-and-recovery oxygen pattern that mimics obstructive sleep apnea in humans.
Under those conditions, the ApoE mice accumulated the expected plaque in the aorta and aortic arch. The ApoE/FXR mice developed significantly less. Some plaque still appeared in the pulmonary artery, suggesting FXR is part of the systemic arterial signature of sleep apnea without erasing it entirely. Fecal samples told a parallel story: the double-knockout animals' gut microbiomes and metabolomes shifted less under hypoxia than those of the ApoE mice.
The proposed mechanism is specific. Gut bacteria chemically modify primary bile acids produced by the liver into secondary forms that act on FXR. When oxygen drops repeatedly, that signaling changes, and the artery wall responds with inflammation and plaque growth. Block the receptor, the team's results suggest, and the plaque signal softens.
This is one candidate mechanism among several under investigation for sleep apnea's cardiovascular toll. Others include sympathetic nervous system overactivation, oxidative stress from reoxygenation, and direct effects of intermittent hypoxia on endothelial cells. The Allaband lab's contribution is to add a gut-to-liver-to-artery axis to that list, anchored in a defined receptor and a defined class of microbial metabolites rather than vague "dysbiosis."
The limits of the data are also specific. The findings were presented as a conference talk, not published in a peer-reviewed journal, and they come entirely from mice engineered to be atherosclerosis-prone. Obstructive sleep apnea in humans is a heterogeneous disease driven by airway collapse, fragmented sleep, and intermittent hypoxia in patients whose cardiovascular baselines vary widely. A pathway that operates in ApoE/FXR double-knockout mice under controlled hypoxia may or may not dominate in patients whose FXR is intact and whose microbiomes have been shaped by years of diet, medication, and disease.
Allaband outlined a clear agenda to test that question. The team plans to reanalyze existing human sleep apnea datasets for bile acid and microbiome signatures, run supplementation studies with specific bile acids, and probe whether a defined microbial consortium could substitute for pharmacological FXR modulation. Those are research steps, not clinical ones. CPAP and other established sleep apnea treatments remain the standard of care for reducing cardiovascular risk; the bile acid axis is, at best, a candidate adjunct.
What the work does offer is a sharper target. If human data reproduce the FXR signal, the field would have a defined receptor, a defined metabolite class, and a defined microbial community to manipulate, rather than a generic appeal to "gut health." That specificity is what makes the result worth following, even at the conference stage where it currently sits.
The next checkpoints to watch are the formal publication of the mouse work, the human dataset reanalyses, and any early bile acid or probiotic intervention studies. Until those land, the gut-to-artery story in sleep apnea is a plausible, mechanistically interesting lead, not a treatment.